Nuvation Bio Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nuvation Bio Inc. on January 8, 2024. The filing reports a corporate governance event: the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of Robert Mashal, M.D., to fill a vacant Board seat. Dr. Mashal serves as a Class II director with an initial term expiring at the 2026 Annual Meeting of Stockholders. He has not been appointed to any Board committees as of the filing date.
Compensation and Governance Details
- Initial Grant: Dr. Mashal received an option grant for Class A Common Stock with an aggregate value of $770,000, vesting monthly over three years.
- Annual Retainer: He is eligible for an annual cash retainer of $40,000 for Board service.
- Committee Compensation: Additional cash retainers apply if he is appointed to a committee.
- Independence: The Board determined Dr. Mashal qualifies as an independent director under NYSE listing rules.
- Background: Dr. Mashal brings experience as a former Global Head of Strategy at Sanofi, CEO of NKT Therapeutics and Alinea Pharmaceuticals, and a partner at Boston Millennia Partners.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the $770,000 option grant in subsequent filings.
- Monitor future announcements regarding Dr. Mashal's potential appointment to specific Board committees.
- Review the Company's latest 10-K or 10-Q for current financial health, as this 8-K contains no financial metrics.
- Confirm the total number of Board seats and the status of other director terms.